Mesenchymal stem cells and uses therefor

Patent metadata

Field	Value
Publication number	US-9943547-B2
Application number	US-201314087830-A
Country	US
Kind code	B2
Filing date	Nov 22, 2013
Priority date	Mar 22, 2004
Publication date	Apr 17, 2018
Grant date	Apr 17, 2018

Abstract

Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.

First claim

The invention claimed is:

1. A method of reducing inflammation associated with graft-versus-host disease in a human in need thereof, comprising the step of
intravenously or intraarterially administering to a human having graft-versus-host disease associated inflammation a suspension of cells in a therapeutic amount effective to reduce the inflammation, and
wherein the cells comprise genetically unmanipulated cultured allogeneic mesenchymal stem cells.

2. The method of claim 1 , wherein the suspension further comprises an acceptable pharmaceutical carrier.

3. The method of claim 2 , wherein the acceptable pharmaceutical carrier is a pharmaceutically acceptable liquid medium for injection.

4. The method of claim 1 , wherein the suspension is administered in an amount of from about 1×10 5 cells/kg to about 1×10 7 cells/kg.

5. The method of claim 1 , wherein the suspension is administered in an amount of from about 1×10 6 cells/kg to about 5×10 6 cells/kg.

6. The method of claim 1 , wherein the inflammation is inflammation in the gut.

7. The method of claim 1 , wherein the cells are isolated from marrow.

8. The method of claim 7 , wherein the marrow is iliac crest marrow.

9. The method of claim 1 , wherein the administration is intravenous.

10. The method of claim 1 , wherein the administration is intraarterial.

11. A method of reducing inflammation in the gut of a human comprising intravenously or intraarterially administering to a human suffering from inflammation of the gut a suspension of cells in a therapeutically effective amount to reduce the inflammation, wherein the cells comprise genetically unmanipulated cultured allogeneic mesenchymal stem cells.

12. The method of claim 11 , wherein the suspension further comprises an acceptable pharmaceutical carrier.

13. The method of claim 12 , wherein the acceptable pharmaceutical carrier is a pharmaceutically acceptable liquid medium for injection.

14. The method of claim 11 , wherein the suspension is administered in an amount of from about 1×10 5 cells/kg to about 1×10 7 cells/kg.

15. The method of claim 11 , wherein the suspension is administered in an amount of from about 1×10 6 cells/kg to about 5×10 6 cells/kg.

16. The method of claim 11 , wherein the cells are isolated from marrow.

17. The method of claim 16 , wherein the marrow is ileac crest marrow.

18. The method of claim 11 , wherein the administration is intravenous.

19. The method of claim 11 , wherein the administration is intraarterial.

20. The method of claim 1 , wherein the cells consist of genetically unmanipulated cultured allogeneic mesenchymal stem cells.

21. The method of claim 11 , wherein the cells consist of genetically unmanipulated cultured allogeneic mesenchymal stem cells.

Assignees

• Mesoblast Int Sarl
• Mesoblast Int Sarl

Inventors

• Aggarwal Sudeepta
• Pittenger Mark F
• Varney Timothy

Classifications

• A61P5/14

  of the thyroid hormones, e.g. T3, T4 · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P7/06

  Antianaemics · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title